Evidence map›Paper›PMID 28110911›Full record

Trial reportThe lancet. Diabetes & endocrinology2017

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02054897. Cited by 365 papers, 24 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
365citing papers in PubMed, 24 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02054897 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Ran2014Enrolled388Registered outcomes6Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide
PMID 29862621PMID 30615985PMID 29748996PMID 30865526PMID 30047216PMID 29687620PMID 29766634PMID 30938762PMID 29907893other papers from this trial
Open the trial in the graph
NCT05870462 phase4unknown statusstarted 2023, after this paper: background citation

Semaglutide and Vascular Regeneration in People With Diabetes and/or Obesity

Ran2023Enrolled100Registered outcomes4Posted comparisons0ConditionsAtherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, ObesityArmsSemaglutide Pen Injector
PMID 27633186PMID 17098089PMID 23973684PMID 34849704PMID 34425083PMID 33554145PMID 33205058PMID 32306097PMID 31477497PMID 30847424other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

365 citing papers in PubMed, 24 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

305 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Christopher SorliBillings Clinic Research Center, Billings, MT, USA. Electronic address: chrissorli@gmail.com.
Shin-Ichi HarashimaGraduate School of Medicine, Kyoto University, Kyoto, Japan.
George M TsoukasDepartment of Medicine, McGill University, Montreal, QC, Canada.
Jeffrey UngerCatalina Research Institute, Chino, CA, USA.
Julie Derving KarsbølNovo Nordisk A/S, Søborg, Denmark.
Thomas HansenNovo Nordisk A/S, Søborg, Denmark.
Stephen C BainSchool of Medicine, Swansea University, Swansea, Wales, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients and new therapies are necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabetes. We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive patients with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone.

methodsWe did a double-blind, randomised, parallel-group, international, placebo-controlled phase 3a trial (SUSTAIN 1) at 72 sites in Canada, Italy, Japan, Mexico, Russia, South Africa, UK, and USA (including hospitals, clinical research units, and private offices). Eligible participants were treatment-naive individuals aged 18 years or older with type 2 diabetes treated with only diet and exercise alone for at least 30 days before screening, with a baseline HbA

findingsBetween February 3, 2014, and August 21, 2014, we randomly assigned 388 participants to treatment; 387 received at least one dose of study medication (128 0·5 mg semaglutide, 130 1·0 mg semaglutide, 129 placebo). 17 (13%) of those assigned to 0·5 mg semaglutide, 16 (12%) assigned to 1·0 mg semaglutide, and 14 (11%) assigned to placebo discontinued treatment; the main reason for discontinuation was gastrointestinal adverse events such as nausea. Mean baseline HbA

interpretationSemaglutide significantly improved HbA

fundingNovo Nordisk A/S, Denmark.

Indexed as

Body WeightDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedPlacebo EffectSemaglutideTreatment OutcomeGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutide

Identifiers

PMID28110911

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.